How clinicians might think about this (risk vs benefit) GLP-1 receptor agonists have benefits that are not small: strong glucose lowering in many patients weight loss benefits in certain populations, cardiovascular risk reduction sometimes improved adherence compared to multiple daily pills because of weekly dosing options So for many patients, the benefit side of the equation is heavy
Fill in the reason for your visit and select Complete
In clinical trials investigating transdermal GLP-1 delivery systems, researchers have explored various wearing durations, including daily and weekly applications
Viking therapeutics recently posted strong weight loss data for its weekly injectable GLP-1/GIP drug (VK2735) in a small Phase 1 trial
Oral Wegovy has demonstrated meaningful average weight loss in clinical trials, while injectable options remain highly effective and well-studied
Count on a producer to deliver the highest compliment in audio: I think theres a lot of mastery to her restraint, Holysz says
